Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis Group has received approval from the FDA to market bupropion hydrochloride extended-release tablets 300mg. Distribution of the product will commence immediately.
Subscribe to our email newsletter
Bupropion hydrochloride extended-release tablets (XL), available in 300mg strength, are the generic equivalent of Wellbutrin XL for the treatment of major depressive disorder.
Douglas Boothe, CEO of Actavis, said: “Bupropion XL compliments our existing Buproprion SR offerings and expands the dosage options for our customers and patients. This approval also highlights Actavis Group’s focus and expertise in bringing complex controlled-release technologies to the marketplace.”